Registration Dossier

Administrative data

Description of key information

Acute Oral Toxicity (rat) = 500 mg/kg bw, OECD 423, van Huygevoort (2010)

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
25 august - 11 september 2009
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Remarks:
Performed according to OECD / EC test guidelines and GLP compliant
Qualifier:
according to
Guideline:
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
Deviations:
no
Qualifier:
according to
Guideline:
EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
Deviations:
no
Qualifier:
according to
Guideline:
EPA OPPTS 870.1100 (Acute Oral Toxicity)
Deviations:
no
GLP compliance:
yes
Test type:
acute toxic class method
Limit test:
no
Species:
rat
Strain:
Wistar
Sex:
female
Details on test animals and environmental conditions:
SpeciesRat, Wistar strain Crl:WI (Han) (outbred, SPF-Quality). Recognized by international guidelines as the recommended test system (e.g. OECD, EC).Source: Charles River Deutschland, Sulzfeld, Germany.Number of animals9 Females (nulliparous and non-pregnant). Each dose group consisted of 3 animals.Age and body weightYoung adult animals (approx. 9 weeks old) were selected. Body weight variation did not exceed +/- 20% of the sex meanConditionsAnimals were housed in a controlled environment, in which optimal conditions were considered to be approximately 15 air changes per hour, a temperature of 21.0 ± 3.0ºC (actual range: 19.6 - 20.9ºC), a relative humidity of 40-70% (actual range: 42 - 76%) and 12 hours artificial fluorescent light and 12 hours darkness per day.Cleaning procedures in the room might have caused the temporary fluctuations above the optimal maximum level of 70% for relative humidity. Based on laboratory historical data, these fluctuations were considered not to have affected the study integrity.AccommodationGroup housing of 3 animals per cage in labeled Macrolon cages (MIV type; height 18 cm.) containing sterilized sawdust as bedding material (Litalabo, S.P.P.S., Argenteuil, France) and paper as cage-enrichment (Enviro-dri, Wm. Lillico & Son (Wonham Mill Ltd), Surrey, United Kingdom). Acclimatization period was at least 5 days before start of treatment under laboratory conditions.DietFree access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany). WaterFree access to tap water. Results of analysis for diet (nutrients and contaminants), sawdust, paper and water were assessed and did not reveal any findings that were considered to have affected the study integrity. All certificates and results of analysis are retained in the NOTOX archives.
Route of administration:
oral: gavage
Vehicle:
unchanged (no vehicle)
Details on oral exposure:
The test substance was dosed undiluted as delivered by the sponsor. Adjustment was made for the density (1.0202) and the water content (66.44%) of the substance. Method: Oral gavage, using plastic feeding tubes.Fasting: Animals were deprived of food overnight prior to dosing and until 3-4 hours after administration of the test substance. Water was available.Frequency: Single dosage, on Day 1.
Doses:
2000 mg Hexahydro-1,3,5-Trimethyl-S-Triazine /kg (10 mL/kg) body weight (or 6000 mg/kg not corrected for water content).300 mg Hexahydro-1,3,5-Trimethyl-S-Triazine /kg (10 mL/kg) body weight (or 894 mg/kg not corrected for water content).
No. of animals per sex per dose:
3 females at 2000 mg/kg6 females at 300 mg/kg
Control animals:
no
Details on study design:
The toxicity of the test substance was assessed by stepwise treatment of groups of 3 females. The first group was treated at a dose level of 300 mg/kg. The absence or presence of mortality of animals dosed at one step determined the next step, based on the test procedure defined in the guidelines, except that the second group was treated at 2000 and the third at 300 mg/kg. This was done for logistic reasons and did not affect the integrity of the study. The onset, duration and severity of the signs of toxicity were taken into account for determination of the time interval between the dose groups.
Key result
Sex:
female
Dose descriptor:
LD50
Effect level:
> 300 - < 2 000 mg/kg bw
Based on:
other: Hexahydro-1,3,5-trimethyl-1,3,5-triazine
Remarks on result:
other: NO 95 % CL as study was class method
Mortality:
All three females dosed at 2000 mg/kg and one (out of six) females dosed at 300 mg/kg were found dead on Days 1 or 2 post-treatment.
Clinical signs:
Hunched posture and/or piloerection were noted among the animals treated at 300 mg/kg between Days 1 and 10. Animals dosed at 2000 mg/kg showed a moribund condition and clonic spasms prior to death.
Body weight:
The mean body weight gain shown by the animals over the study period was considered to be normal.
Gross pathology:
Reddish discolouration of the glandular mucosa of the stomach was found in the animals that died during the study, at macroscopic post mortem examination. Macroscopic examination of the surviving animals at termination did not reveal any abnormalities.
Interpretation of results:
harmful
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
The oral LD50 value of HEXAHYDRO-1,3,5-TRIMETHYL-S-TRIAZINE in Wistar rats was established to be within the range of 300-2000 mg/kg body weight.According to the OECD 423 test guideline, the LD50 cut-off value was considered to be 500 mg/kg body weight.
Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
500 mg/kg bw

Acute toxicity: via inhalation route

Link to relevant study records
Reference
Endpoint:
acute toxicity: inhalation
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
the study does not need to be conducted because the substance is classified as corrosive to the skin
Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Link to relevant study records
Reference
Endpoint:
acute toxicity: dermal
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
the study does not need to be conducted because the substance is classified as corrosive to the skin
Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

An assessment of the acute toxicity of hexahydro-1,3,5-trimethyl-1,3,5-triazine is made based on one key study on the oral route (van Huygevoort, 2010). This study estimated that the oral LD50 of hexahydro-1,3,5-trimethyl-1,3,5-triazine in rats to be between 300 and 2000 mg/kg bw using the acute toxic class method, with an LD50 cut-off value of 500 mg/kg bw.


Justification for selection of acute toxicity – oral endpoint
This study is the only acute oral toxicity study available and meets the requirements of international testing guidelines.

Justification for classification or non-classification

According to the criteria for classification and labelling of substances and mixtures (Regulation (EC) No. 1272/2008), hexahydro-1,3,5-trimethyl-1,3,5-triazine qualifies for classification as “Acutely Toxic Category 4” (H302).